Home>Topics>Stocks>Affymax

Affymax AFFY

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Affymax reports Q2 profit

      Headlines

      Thu, 31 Jul 2014

      Affymax ( OTCQB: AFFY ): Q2 EPS of $0.19. Press Release Post your comment!

    2. Affymax may consider filing for bankruptcy; cuts workforce by 75 percent

      Headlines

      Mon, 18 Mar 2013

      (Reuters) - Drug maker Affymax Inc said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives as it struggles with the recent recall of its sole commercial product, the anemia drug Omontys.

    3. Affymax may consider filing for bankruptcy; cuts workforce by 75 pct

      Headlines

      Mon, 18 Mar 2013

      March 18 (Reuters) - Affymax Inc, which recalled its anemia drug Omontys in February, said it may consider selling itself or filing for bankruptcy among a range of strategic alternatives.

    4. Affymax stock plunges 85 percent on drug recall

      Headlines

      Mon, 25 Feb 2013

      (Reuters) - Shares of Affymax Inc fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.

    5. Amgen's Enbrel Sees Outstanding 2012, but Neulasta Worries Keep Our Long-Term Forecast Conservative

      Commentary

      Thu, 24 Jan 2013

      Aranesp pressure was expected, and Epogen declines appear to be caused more by competition (albeit minimal) from Affymax 's AFFY Omontys and less from the decreased ESA usage due to bundled reimbursement that has plagued growth in previous quarters

    6. No Surprises in Amgen's First Quarter; Raising Our Fair Value Estimate on Pipeline Progress

      Commentary

      Tue, 24 Apr 2012

      operators DaVita DVA and Fresenius FMS, we think future biosimilar competition--as well as branded products like Affymax 's AFFY recently approved anemia drug Omontys--cloud Epogen's long-term prospects. We're forecasting continued double

    7. Amgen's Micromet Acquisition and Strong 2012 Outlook Are Positives, but Shares Look Fairly Valued

      Commentary

      Thu, 26 Jan 2012

      sign for near-term sales. However, the DaVita deal only covers one third of the U.S. dialysis market, and Affymax 's AFFY Hematide--a more convenient and potentially cheaper option in a price-sensitive market--could receive Food

    8. Dropping Coverage of Affymax

      Commentary

      Mon, 11 Oct 2010

      We are dropping coverage of Affymax AFFY to focus our resources elsewhere.

    9. Affymax Updates Hematide Approval Plan

      Commentary

      Thu, 5 Aug 2010

      Affymax AFFY and partner Takeda announced Thursday their preliminary strategy toward ..... keeping our fair value estimate in place until we hear details regarding Affymax 's meeting with the FDA . As a reminder , the frequency of cardiovascular

    10. Lowering Affymax's Fair Value

      Commentary

      Mon, 28 Jun 2010

      lowering our fair value estimate for Affymax AFFY following the release of clinical ..... cardiovascular concerns), and we now think Affymax 's chances of winning approval ..... market for predialysis, we think Affymax and partner Takeda will need to

    « Prev12Next »
    Content Partners